Lymphoma Clinical Trials

USOR #19062

A Phase 1B/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of Tazemetostat or placebo in combination with Lenalidomide plus Rituximab in subjects with relapsed/refractory follicular lymphoma. (EZH-302)